Life Science Nation attends many partnering conferences, in addition to hosting our own quarterly Redefining Early Stage Investments (RESI) Conference series. After taking the time to study the most successful partnering requests and interviewing investors about what they look for in an introductory note, we have created a template email, which should increase your response rate when soliciting investment:

My name is John Doe, CEO, Sample Therapeutics, an early stage therapeutic company based out of New York developing an antibody drug conjugate (ADC) for pancreatic cancer. Our lead asset (OK-101) is in the middle of Phase 1 clinical trials and is open to partnership opportunities...

   READ MORE   

If you're developing a biotech asset and you're raising funds in order to complete pre-IND studies, or to embark on your first human clinical trial, this panel will provide an opportunity to hear from investors who focus on companies at this challenging stage of the development process.

Moderated by Steven Gullans, Managing Director, Excel Venture Management, this panel features:

These investors will offer their insights on the challenge of assessing a biotech opportunity prior to attaining human proof of concept data...

   READ MORE   

To wrap up the entire Summer Reading Series we bring you an article we wrote for Nature Magazine entitled "The View Beyond Venture Capital". This piece discusses many of the shifts that are currently taking place in the life science investment ecosystem including the rise in relevance of family offices for early stage life science companies, different types of investor mandates, the changing role of Big Pharma, and more.

It has been our pleasure to share these past 15 issues of the LSN Summer Reading Series with you and we hope you found some practices to bring back to you own campaign. If you missed out on any chapters thus far here are the links...

   READ MORE